CNS drug development - lost in translation?

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 959-970

  Talevi, A ^a,b   Bellera, C L ^a,b   Di Ianni, M ^a,b   Gantner, M ^a   Bruno Blanch, L E ^a   Castro, E A ^c  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c INSTITUTO DE INVESTIGACIONES FISICOQUÍMICAS TEÓRICAS Y APLICADAS INIFTA   (Argentina)

Author keywords

ADMET models; Biomarkers; CNS drugs; In silico models; In vitro models; Multi target directed ligands

Indexed keywords

ATAZANAVIR; BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; CHOLINESTERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GABAPENTIN; INOSITOL; LEVODOPA; PACLITAXEL; POLOXAMER; VALPROIC ACID; XENOBIOTIC AGENT;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; DRUG BIOAVAILABILITY; DRUG SCREENING; HUMAN; IN VITRO STUDY; NEUROPHARMACOLOGY; NONHUMAN;

ANIMALS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; COMPUTER-AIDED DESIGN; DRUG DISCOVERY; HUMANS;

EID: 84866345665     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955712802762356     Document Type: Article

References (139)

1. Morgan, S.; Grootendorst, P.; Lexchin, J.; Cunningham, C.; Greyson, D. The cost of drug development: A systematic review. Health Policy., 2011, 100, 4-17.
2. Paul, S. M.; Mytelka, D. A.; Dunwiddie, C. T.; Pesinger, B. H.; Munos, B. H.; Lindborg, S. R.; Schacht, A. L. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Rev. Drug Discov., 2010, 9, 203-214.
3. Pammolli, F; Magazzini, L; Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nature Rev. Drug Discov., 2011, 10, 428-438.
4. Koenig, J. Does process excellence handcuff drug development? Drug Discov. Today, 2011, 16, 377-381.
5. United States Government Accountability Office (GAO) Report to Congressional Requesters. New Drug Development. Science, business, regulatory, and intellectual property issues cited as hampering drug development efforts, 2006.
6. Hurko, O.; Ryan, J. L. Translational research in Central Nervous System drug discovery. NeuroRx, 2005, 2, 671-682.
7. Pangalos, M. N.; Schechter, L. E.; Hurko, O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov., 2007, 6, 521-532.
8. Wager, T. T.; Villalobos, A.; Verhoest, P. R.; Hou, X.; Shaffer, C. L. Strategies to optimize the brain availability of central nervous system drug candidates. Expert Opin. Drug Discov., 2011, 6, 371-381.
9. Tang, Z.-M. New drugs approved by US FDA in 2007 and problems and suggestions. Chinese J. New Drugs, 2008, 17, 988-992.
10. Franson, T. R. Has the FDA Amendments Act of 2007 impaired drug development? Clin. Pharmacol. Ther., 2011, 89, 169-171.
11. Corey, G. R.; Stryjewski, M. E. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. Clin. Infect. Dis., 2011, 52, S469-S476.
12. Filmore, D.; Thayer, A. M.; Willis, R. C. Pipeline challenges. Major pharmaceutical and biotechnology companies take a variety of approaches to remain productive. Modern Drug Discov., 2004, 7, 28-34.
13. Musk, P. Magic shotgun methods for developing drugs for CNS disorders. Discov. Med., 2004, 4, 299-302.
14. Roth, B. L.; Sheffler, D. J.; Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov., 2004, 3, 353-359.
15. Jeffrey, P.; Summerfield, S. Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol. Dis., 2010, 33-37.
16. Redzic, Z. Molecular biology of the blood-brain and the bloodcerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS, 2011, 8, 3.
17. Löscher, W.; Potschka, H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol., 2005, 76, 22-76.
18. Begley, D. J. In: Blood-spinal cord and brain barriers in health and disease; Sharma H. S. and Westman J., Eds.; Elsevier Academic Press: San Diego, 2004; pp. 83-97.
19. Hawkins, BT; Davis, TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev., 2005, 75, 173-185.
20. Talevi, A.; Bruno-Blanch, L. E. In: The blood-brain barrier: new research. Montenegro P. A. and Juárez S. M., Eds.; Nova publishers, in press.
21. Cardoso, F. L.; Brites, D.; Brito, M. A. Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches. Brain Res. Rev., 2010, 64, 328-363.
22. Maurer, T. S.; DeBartolo, D. B.; Tess, D. A.; Scott, D. O. Relationship between exposure and nonspecific binding of thirtythree central nervous system drugs in mice. Drug Metab. Dispos., 2005, 33, 175-181.
23. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cinfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E. C. A. et al. Drug Metab. Dipos., 2005, 33, 165-174.
24. van de Waterbeemd, H.; Smith, D. A.; Jones, B. C. Lipophilicity in PK design: methyl, ethyl, futile. J. Comput. Aided Mol. Des., 2001, 15, 273-286.
25. Liu, X.; Chen, C.; Smith, B. J. Progress in brain penetration evaluation in drug discovery. J. Pharmacol. Exp. Ther., 2008, 325, 349-356.
26. Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M. D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem. Neurosci, 2010, 1, 420-434.
27. Debnath, A. K.; López de Compadre, R. L.; Debnath, G.; Shusterman, A. J.; Hansch, C. Structure-activity relationship of mutagenic aromatic and heteroaromatic nitro compounds. Correlation with molecular orbital energies and hydrophobicity. J. Med. Chem., 1991, 34, 786-797.
28. Debnath, A. K.; Shusterman, A. J.; López de Compadre, R. L.; Hansch, C. International Comission for Protection Against Environmental Mutagens and Carcinogens. The importance of the hydrophobic interaction in the mutagenicity of organic compounds. Mutat. Res., 1994, 305, 63-72.
29. Testa, B.; Krämer, S. D. The biochemistry of drug meta - An introduction. Part 5. Metabolism and bioactivity. Chem. Biodivers., 2009, 6, 591-684.
30. Smith, C. J.; Hansch, C. The relative toxicity of compounds in mainstream cigarette smoke condensate. Food Chem. Toxicol., 2000, 38, 637-646.
31. Wager, T. T.; Hou, X; Verhoest, P. R.; Villalobos, A. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem. Neurosci, 2010, 1, 435-449.
32. Talevi, A.; Cravero, M. S.; Castro, E. A.; Bruno-Blanch, L. E. Discovery of anticonvulsant activity of abietic acid through application of linear discriminant analysis. Bioorg. Med. Chem. Lett., 2007, 17, 1684-1690.
33. Talevi, A.; Bellera, C. L.; Castro, E. A.; Bruno-Blanch, L. E. A successful virtual screening application: prediction of anticonvulsant activity in MES test of widely used pharmaceutical and food preservatives methylparaben and propylparaben. J. Comput. Aided Mol. Des., 2007, 21, 527-538.
34. Gavernet, L.; Talevi, A.; Castro, E. A.; Bruno-Blanch, L. E. A combined virtual screening 2D and 3D QSAR methodology for the selection of new anticonvulsant candidates from a natural product library. QSAR Comb. Sci., 2008, 27, 1120-1129.
35. di Ianni, M.; Talevi, A.; Castro, E. A.; Bruno-Blanch, L. E. Development of a highly specific ensemble of topological models for early identification of P-glycoprotein substrates. J. Chemometr., 2011, 25, 313-322.
36. Bodor, N.; Moon, S. C.; Bruno-Blanch, L. E. Synthesis and pharmacological evaluation of prodrugs of valproic acid. Pharmazie, 2000, 55, 184-186.
37. Moon, S. C.; Echeverria, G. A.; Punte, G.; Ellena, J.; Bruno-Blanch, L. E. Crystal structure and anticonvulsant activity of (+/-)-1,2:4,5-di-O-isopropylidene-3,6-di-O-(2-propylpentanoyl)-myoinositol. Carbohydr. Res., 2007, 342, 1456-1461.
38. Bruno-Blanch, L.; Moon, S. C. U.S. Patent 7,763,650, 2010.
39. Fenili, D.; Weng, Y-Q.; Aubert, I.; Nitz, M.; McLaurin, J. Sodium/myo-Inositol transporters: substrate transport requeriments and regional brain expression in the TgCRND8 mouse model of amyloid pathology. PloS One, 2011, 6, e24032.
40. Dauchy, S.; Dutheil, F.; Weaver, R. J.; Chassoux, F.; Daumas-Duport, C.; Couraud, P. O.; Schermann, J. M.; De Waziers, I.; Declèves, X. ABC transporters, cytochromes P450 and their main transcription factors: Expression at the human blood-brain barrier. J. Neurochem., 2008, 107, 1518-1528
41. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J. Neurochem., 2011, 117, 333-345.
42. Shawahna, R.; Uchida, Y.; Decleves, X.; Ohtsuki, S.; Yousif, S.; Dauchy, S.; Jacob, A.; Chassoux, F.; Daumas-Duport, C.; Couraud, P.-O.; Terasaki, T.; Scherrmann, J.-M. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol. Pharm., 2011, 8, 1332-1341.
43. US Food and Drug Administration. Draft Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling, 2006.
44. European Medicines Agenc. Guideline on the Investigation of Drug Interactions, 2010.
45. Zhang, L; Zhang, Y.; Strong, J. M.; Reynolds, K. S.; Huang, S.-M. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica, 2008, 38, 709-724.
46. Elsby, R.; Fox, L.; Stresser, D.; Layton, M.; Butters, C.; Sharma, P.; Smith, V.; Surry, D. In vitrorisk assessment of AZD9056 perpetrating transporter-mediated drug-drug interaction with methotrexate. Eur. J. Pharm. Sci., 2011, 43, 41-49.
47. Cisternino, S.; Mercier, C.; Bourasset, F.; Roux, F.; Scherrmann, J. M. Expression, up-regulation, and transport activity of the multidrug-resistance protein abcg2 at the mouse blood-brain barrier. Cancer Res., 2004, 64, 3296-3301.
48. Bark, H.; Xu, H. D.; Kim, S. H.; Yun, J.; Choi, C. H. Pglycoprotein down-regulates expression of breast cancer resistance protein in a drug-free state. FEBS Lett., 2008, 582, 2595-2600.
49. Choi, C. H.; Kim, S. H.; Rha, H. S.; Jeong, J. H.; Park, Y. H; Min, Y. D.; Kee, K. H.; Lim, D. Y. Drug concentration-dependent expression of multidrug resistance-associated protein and Pglycoprotein in the doxorubicin-resistant acute myelogenous leukemia sublines. Mol. Cell., 1999, 9, 314-319.
50. Bordow, S. B.; Haber, M.; Madafiglio, J.; Cheung, B.; Marshall, G. M.; Norris, M. D. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res., 1994, 54, 5036-5040.
51. Miller, D. S.; Bauer, B.; Hartz, A. M. S. Modulation of Pglycoprotein at the blood-brain barrier: opportunities to improve CNS pharmacotherapy. Pharmacol. Rev., 2008, 60, 196-209.
52. Miller, D. S. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol. Sci., 2010, 31, 246-254.
53. Polli, J. W.; Olson, K. L.; Chism, J. P.; St. John Williams L.; Yeager, R. L.; Wooddard, S. M.; Otto, V.; Castellino, S.; Demby, V. E. An unexpected synergist role of P-Glycoprotein and Breast Cancer Resistance Protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). Drug Metab. Dispos., 2009, 37, 439-442.
54. de Vries, N. A.; Zhao, J.; Kroon, E.; Buckle, T.; Beijnen, J. H.; van Tellingen O. P-glycoprotein and Breast Cancer Resistance Protein: Two dominant transporters working together in limiting the brain penetration of topotecan. Clin. Cancer Res., 2007, 13, 6440-6449.
55. Deeken, J. F.; Löscher, W. The blood-brain barrier and cancer: Transporters, treatment and Trojan horses. Clin. Cancer. Res., 2007, 13, 1663-1674.
56. Lhommé, C.; Joly, F.; Walker, J. L.; Lissoni, A. A.; Nicoletto, M. O.; Manikhas, G. M.; Baekelandt, M. M.; Gordon, A. N.; Fracasso, P. M.; Mietlowski, W. L.; Jones, G. J.; Dugan, M. H. Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer. J. Clin. Oncol. 2008, 26, 2674-2682.
57. Tiwari, A.; Sodani, K.; Dai, C. L.; Ashby, C. R.; Chen, Z. S. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr. Pharm. Biotechnol., 2011, 12, 570-594.
58. Akhtar, N.; Ahad, A.; Khar, R. K.; Jaggi, M.; Ágil, M.; Igbal, Z.; Ahmad, F. J.; Talegaonkar, S. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert. Opin. Ther. Pat., 2011, 21, 561-576.
59. Hartz, A. M.; Bauer, B. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol. Interv., 2010, 10, 293-304.
60. Demel, M. A.; Schwha, R.; Krämer, O.; Ettmayer, P.; Haaksma, E. E.; Ecker, G. F. In silico prediction of substrate properties for ABC-mulridrug transporters. Expert Opin. Drug. Metab. Toxicol, 2008, 4, 1167-1180.
61. Demel, M. A.; Krämer, O.; Ettmayer, P.; Haaksma, E. E.; Ecker, G. F. Predicting ligand interactions with ABC tansporters in ADME. Chem. Biodivers., 2009, 6, 1960-1969.
62. Aller, S.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.; Trinh, Y.; Zhang, Q.; Urbatsch, I.; Chang, G. Structure of Pglycoprotein reveals a molecular basis for poly-specific drug binding. Science, 2009, 323, 1718-1722.
63. Tarcsay, A.; Keseru, G. M. Homology modeling and binding site assessment of the human P-glycoprotein. Future Med. Chem., 2011, 3, 297-307.
64. Penzotti, J.; Lamb, M.; Eyensen, E.; Grootenhuis, P. A computational ensemble pharmacophore model for indetifying substrates of P-glycoprotein. J. Med. Chem., 2002, 45, 1737-1740.
65. Xue, Y.; Yap, C.; Sun, L.; Cao, Z.; Wang, J.; Chen, Y. Prediction of P-glycoprotein substrates by a support vector machine approach. J. Chem. Inf. Comput. Sci., 2004, 44, 1497-1505.
66. Cerqueira Lima, P.; Golbraikh, A.; Oloff, S.; Xiao, Y.; Tropsha, A. Combinatorial QSAR modeling of P-glycoprotein substrates. J. Chem. Inf. Model., 2006, 46, 1245-1254.
67. Ciancheta, G.; Singleton, R.; Zhang, M.; Wildgoose, M.; Giesing, D.; Fravolini, A.; Cruciani, G.; Vaz, R. A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRINDbased 3D-QSAR. J. Med. Chem., 2005, 48, 2927-2935.
68. Zhang, L.; Balimane, P.; Johnson, S.; Chong, S. Development of an in silico model for predicting efflux substrates in Caco-2 cells. Int. J. Pharm., 2007, 343, 98-105.
69. Li, W.; Li, L.; Eksterowicz, J.; Ling, X.; Cardozo, M. Significance analysis and multiple pharmacophore models for differentiating Pglycoprotein substrates. J. Chem. Inf. Model., 2007, 47, 2429-2438.
70. Chang, C.; Bahadduri, P.; Polli, J.; Swaan, P.; Ekins, S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab. Dispos., 2006, 34, 1976-1984.
71. Ekins, S.; Kim, R.; Leake, B.; Dantzig, A.; Schuetz, E.; Lan, L.; Yasuda, K.; Shepard, R.; Winter, M.; Schuetz, J.; Wikel, J.; Wrigton, S. Application of three-dimensional quantitative structure-activity relationships of p-glycoprotein inhibitors and substrates. Mol. Pharmacol., 2002, 61, 974-981.
72. Wang, R; Kuo, C; Lien, L; Lien, E. Structure-activity relationship: analysis of P-Glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther., 2003, 28, 203-228.
73. Boccard, J.; Bajot, F.; Di Pietro, A.; Rudaz, S.; Bournendjel, A.; Nicolle, E.; Carript, P. A 3D linear solvatation energy model to quantify the affinity of flavonoid derivatives toward pglycoprotein. Eur. J. Pharm. Sci., 2009, 36, 254-264.
74. Nakagawa, H.; Saito, H.; Ikegami, Y.; Aida-Hyugaji, S.; Sawasa, S.; Ishikawa, T. Molecular modeling of new camptothecin analogues to curcumvent ABCG2-mediated drug resistance in cancer. Cancer Lett., 2006, 234, 81-89.
75. Wang, Z.; Chen, Y.; Liang, H.; Bender, A.; Glen, R. C.; Yan, A. Pglycoprotein substrate models using support vector machines based on a comprehensive data set. J. Chem. Inf. Model., 2011, 51, 1447-1456.
76. Huang, J.; Ma, G.; Muhammad, I.; Cheng Y. Identifying Pglycoprotein substrates using a support vector machine optimized by a particle swarn. J. Chem. Inf. Model., 2007, 47, 1638-1647.
77. Cabrera, M.; González, I.; Fernández, C.; Navarro, C.; Bermejo, M. A topological substructural approach for the prediction of Pglycoprotein substrates. J. Pharm. Sci., 2006, 95, 589-606.
78. Bansal, T.; Akhtar, N.; Jaggi, M.; Khar, R. K.; Talegaonkar, S. Novel formulation approaches for optimizing delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov. Today., 2009, 14, 1067-1074.
79. Gohel, M. C.; Parikh, R. K.; Modi, S. C.; Vyas, K. G.; Sheth, K. M. Novel drug delivery approaches to bypass P-glycoprotein efflux pump. Pharmaceutical Rev., 2011, 9.
80. Alam, M. I.; Beg, S.; Samad, A.; Baboota, S.; Kohli, K.; Ali, J.; Ahuja, A.; Akbar, M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci., 2010, 40, 385-403.
81. Wong, H. L.; Chattopadhyay, N.; Wu, X. Y.; Bendayan, R. Nanotechnology applications for improved delivery of antiretroviral drugs to the brain. Adv. Drug. Deliv. Rev., 2010, 62, 503-517.
82. Chattopadhyay, N.; Zastre, J.; Wong, H.-L.; Wu, X. Y.; Bendayan, R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm. Res., 2008, 10, 2262-2271.
83. Batrakova, E. V.; Li, S.; Alakhov, V. Y.; Miller, D. W.; Kabanov, A. V. Optimal structure requeriments for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther., 2003, 304, 845-854.
84. Batrakova, E. V.; Li, S.; Miller, D. W.; Kabanov, A. V. Pluronic P85 increases permeability of a borad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res., 1999, 16, 1366-1372.
85. Kabanov, A. V.; Alakhov, V. Y. Pluronic block copolymers in drug delivery from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst., 2002, 19, 1-72.
86. Lo, Y. L. Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. J. Control. Release, 2003, 90, 37-48.
87. © block copolymers. J. Control. Release, 2003, 91, 75-81.
88. European Commission, European Federation of Pharmaceutical Industries and Associations. The Innovative Medicines Initiative (IMI) Strategic Search Agenda, 2006.
89. Aronica, E.; Gorter, J. A.; Ramkema, M.; Redeker, S.; Ozbas-Gerçeker, F.; van Vliet, E. A.; Scheffer, G. L.; Scheper, R. J.; van der Valk, P.; Baaven, J. C.; Troost, D. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia, 2004, 45, 441-451.
90. Dombrowski, S. M.; Desai, S. Y.; Marroni, M.; Cucullo, L.; Goodrich, K.; Bingaman, W.; Mayberg, M. R.; Bengez, L.; Janigro, D. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia, 2001, 42, 1501-1506.
91. Sisodiya, S. M.; Martinian, L.; Scheffer, G. L.; van der Valk, P.; Scheper, R. J.; Harding, B. N.; Thom, M. Vascular colocalization of P-glycoprotein, multidrug resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. Neuropathol. Appl. Neurobiol., 2006, 32, 51-63.
92. Aronica, E.; Gorter, J. A.; Jansen, G. H.; van Veelen, C. W.; van Rijen, P. C.; Leenstra, S.; Ramkema, M.; Scheffer, G. L.; Scheper, R. J.; Troost, D. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: focal cortical dysplasia and glioneuronal tumors. Neurosc., 2003, 118, 417-429.
93. Ak, H.; Ay, B.; Tanrivedi, T.; Sanus, G. Z.; Is, M.; Sar, M.; Oz, B.; Ozkara, C.; Ozyurt, E.; Uzan, M. Expression and cellular distribution of multidrug resistance-related proteins in patients with focal cortical dysplasia. Seizure, 2007, 16, 493-503.
94. Aronica, E.; Gorter, J. A.; Redeker, S.; van Vliet, E. A.; Ramkema, M.; Scheffer, G. L.; Cheper, R. J.; van der Valk, P.; Leenstra, S.; Bayeen, J. C.; Spliet, W. G. M.; Troost, D. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia, 2005, 46, 849-857.
95. Gonzalez-Velasquez, F. J.; Kotarek, J. A.; Moss, M. A. Soluble aggregates of the amyloid-beta protein selectivelt stimulate permeability in human brain microvascular endothelial monolayers. J. Neuroche., 2008, 107, 466-477.
96. Marco, S.; Skaper, S. D. Amyloid beta-peptide1-42 alters tight junction protein distribution and expression in brain microvessel endothelial cells. Neurosci. Lett., 2006, 401, 219-224.
97. Donahue, J. E.; Johanson, C. E. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2008, 67. 261-270.
98. Spudich, A.; Kilic, E.; Xing, H.; Kilic, U.; Renstch, K. M.; Wunderl-Allenspach, H.; Bassetti, C. L.; Hermann, D. M. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nature Neurosci., 2006, 9, 487-488.
99. Dazert, P.; Suofu, Y.; Grube, M.; Popa-Wagner, A.; Kroemer, H. K.; Jedlitschky, G.; Kessler, C. Differential regulation of transport proteins in the periinfarct region following reversible middle cerebral artery occlusion in rats. Neurosci., 2006, 142, 1071-1079.
100. Ueno, M.; Nakagawa, T.; Huang, C. L.; Ueki, M.; Kusaka, T.; Hosomi, N.; Kanenishi, K.; Onodera, M.; Wu, B.; Sakamoto, H. The expression of P-glycoprotein is increased in vessels with blood-brain barrier impairment on a stroke-prone hypertensive model. Neuropathol. Appl. Neurobiol., 2009, 35, 147-155.
101. Koto, T.; Takubo, K.; Ishida, S.; Shinoda, H.; Inoue, M.; Tsubota, K.; Okada, Y.; Ikeda, E. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am. J. Pathol., 2007, 170, 1389-1397.
102. Kago, T.; Takagi, N.; Date, I.; Takenaga, Y.; Takagi, K.; Takeo, S. Cerebral ischemia enhances tyrosine phosphorylation of occluding in brain capillaries. Biochem. Biophys. Res. Commun., 2006, 339, 1197-1203.
103. Mark, K. S.; Davis, T. P. Cerebral microvascular changes in permeability and tight junctions induced by hypoxiareoxygenation. Am. J. Physiol. Heart Circ. Physiol., 2002, 282, H1485-H1494.
104. Löscher, W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res., 2002, 50, 105-123.
105. Löscher, W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure, 2011, 20, 359-368.
106. Löscher, W.; Schmidt, D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia, 52, 657-678.
107. Olson, H.; Betton, G.; Robinson, D.; Thomas, K.; Monro, A.; Kolaja, G.; Lilly, P.; Sanders, J.; Sipes, G.; Bracken, W.; Dorato, M.; van Deun, K; Smith, P.; Berger, B.; Heller, A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol., 2000, 32, 56-67.
108. Kamiie, J.; Ohtsuki, S.; Iwase, R.; Ohmine, K.; Katsukura, Y.; Yanai, K.; Sekine, Y.; Uchida, Y.; Ito, S.; Terasaki, T. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm. Res., 2008, 25, 1469-1483.
109. Dussault, I., Forman, B. M. The nuclear receptor PXR: a master regulator of "homeland" defense. Crit. Rev. Eukaryot. Gene Expr., 2002, 12, 53-64.
110. Xie, W.; Barwick, J. L.; Downes, M.; Blumberg, B.; Simon, C. M.; Nelson, M. C.; Neuschwander-Tetri, B. A.; Brunt, E. M.; Guzelian, P. S.; Evans, R. M. Nature, 2000, 406, 435-439.
111. Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; Troutman, M. D.; de Morais, S. M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dipos., 2008, 36, 268-275.
112. Katoh, M.; Suzuyama, N.; Takeuchi, T.; Yoshitomi, S.; Asahi, S.; Yokoi, T. Kinetic analysis for species differences in Pglycoprotein-mediated drug transport. J. Pharm. Sci., 2006, 95, 2673-2683.
113. Ahmed, S.; Mozley, P. D.; Potter, W. Z. Biomarkers in psychotropic drug development. Am. J. Geriatr. Psychiatry, 2002, 10, 678-686.
114. Sormani, M.P.; Bruzzi, P.; Comi, G.; Filippi, M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology, 2002, 58, 417-421.
115. Kadir, A.; Nordberg, A. Target-specific PET probes for neurodegenerative disorders related to dementia. J. Nucl. Med., 2010, 51, 1418-1430.
116. Nordberg, A. Amyloid imaging in early detection of Alzheimer's disease. Neurodeger. Dis., 2010, 7, 136-138.
117. Hampel, H.; Wilcock, G.; Andrieu, S.; Aisen, P.; Blennow, K.; Broich, K.; Carrillo, M.; Fox, N. C.; Frisoni, G. B.; Isaac, M.; Lovestone, S.; Nordberg, A. et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog. Neurobiol., in press.
118. Kantarci, K.; Jack, C. R. Jr. Neuroimaging in Alzheimer disease: an evidence-based review. Neuroimaging Clin. N. Am., 2003, 13, 197-209.
119. Hurko, O. Biomarkers in brain disease. Ann. N. Y. Acad. Sci., 2009, 1180, 1-10.
120. Sherer, T. B. Biomarkers for Parkinson's disease. Sci. Transl. Med., 2011, 3, 79ps14.
121. Tarawneh, R.; Holtzman, D. M. Biomarkers in translational research of Alzheimer's disease. Neuropharmacol., 2010, 59, 310-322.
122. Bieck, P. R.; Potter, W. Z. Biomarkers in psychotropic drug development: integration of data across multiple domains. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 227-246.
123. Liu, Z.; Zhang, J.; Zhang, A. Design of multivalent ligand targeting G-protein-coupled receptors. Curr. Pharm. Des., 2009, 15, 682-718.
124. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem., 2008, 51, 347-372.
125. Youdim, M. B. H., & Buccadfasco, J. J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci., 2005, 26, 27-35.
126. Bianchi, M. T.; Pathmanathan, J.; Cash, S. S.; From ion channels to complex networks: magic bullets versus magic shotgun approaches to anticonvulsant pharmacotherapy. Med. Hypoytheses, 2009, 72, 297-305.
127. Decker, M.; Lehmann, J. Agonistic and antagonistic bivalent ligands for serotonin and dopamine receptors including their transporters. Curr. Top. Med. Chem., 2007, 7, 347-353.
128. Wong, E. H. F; Tarazi, F. I.; Shahid, M. The effectiveness of multitarget agents in schizophrenia and mood disorders: relevance of receptor signature to clinical action. Pharmacol. Therapeut., 2010, 126, 173-185.
129. Stahl, S. M. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectrums, 2009, 14, 71-73.
130. Wong, E. H. F., Nikam, S. S., & Shahid, M. Multi- and singletarget agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr. Opin. Investig. Drugs, 2008, 9, 28-36.
131. Perucca, E. Clinically relevant drug interactions with antiepileptic drugs. Br. J. Clin. Pharmacol., 2006, 61, 246-255.
132. Ma, X. H.; Shi, Z.; Tan, C.; Jiang, Y.; Go, M. L.; Low, B. C.; Chen, Y. Z. In-silico approaches to multi-target drug discovery. Computer aided multi-target drug design, multi-target virtual screening. Pharm. Res., 2010, 27, 739-749.
133. Stephenson, V. C.; Heyding, R. A.; Weaver, D. F. The "promiscuous drug concept" with applications to Alzheimer's disease. FEBS Lett., 2005, 579, 1338-1342.
134. Bolognesi, M. L.; Cavalli, A.; Melchiorre, C. Memoquin: a multitarget- directed ligand as an innvative opportunity for Alzheimer's disease. NeuroRx, 2009, 6, 152-162.
135. Melchiorre, C.; Andrisano, V.; Bolognesi, M. L.; Budriesi, R.; Cavalli, A.; Cavrini, V; Rosini, M.; Tumiatti, V.; Recanatini, M. Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease. J. Med. Chem., 1998, 41, 4186-4189.
136. Alvárez, A.; Alarcon, R.; Opazo, C.; Campos, E. O.; Munoz, F. J.; Calderón, F. H.; Dajas, F.; Gentry, M. K.; Doctor, B.P.; De Mello, F. G.; Inestrosa, N. C. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the anzyme and increase the neurotoxicity of Alzheimer's fibrils. J. Neurosci., 1998, 18, 3213-3223.
137. Bourne, Y.; Taylor, P.; Bougis, P. E.; Marchot, P. Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly. J. Biol. Chem., 1999, 274, 2963-2970.
138. Bolognesi, M. L.; Cavalli, A.; Valgimigli, L.; Bartolini, M.; Rosini, M.; Andrisano, V. Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease. J. Med. Chem., 2007, 50, 6446-6449.
139. Gaeta, A.; Hider, R. C. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol., 2005, 146, 1041-1059